Literature DB >> 11247913

Respiratory control in humans after 8 h of lowered arterial PO2, hemodilution, or carboxyhemoglobinemia.

X Ren1, K L Dorrington, P A Robbins.   

Abstract

In humans exposed to 8 h of isocapnic hypoxia, there is a progressive increase in ventilation that is associated with an increase in the ventilatory sensitivity to acute hypoxia. To determine the relative roles of lowered arterial PO2 and oxygen content in generating these changes, the acute hypoxic ventilatory response was determined in 11 subjects after four 8-h exposures: 1) protocol IH (isocapnic hypoxia), in which end-tidal PO2 was held at 55 Torr and end-tidal PCO2 was maintained at the preexposure value; 2) protocol PB (phlebotomy), in which 500 ml of venous blood were withdrawn; 3) protocol CO, in which carboxyhemoglobin was maintained at 10% by controlled carbon monoxide inhalation; and 4) protocol C as a control. Both hypoxic sensitivity and ventilation in the absence of hypoxia increased significantly after protocol IH (P < 0.001 and P < 0.005, respectively, ANOVA) but not after the other three protocols. This indicates that it is the reduction in arterial PO2 that is primarily important in generating the increase in the acute hypoxic ventilatory response in prolonged hypoxia. The associated reduction in arterial oxygen content is unlikely to play an important role.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11247913     DOI: 10.1152/jappl.2001.90.4.1189

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  6 in total

1.  A phase I trial of low-dose inhaled carbon monoxide in sepsis-induced ARDS.

Authors:  Laura E Fredenburgh; Mark A Perrella; Diana Barragan-Bradford; Dean R Hess; Elizabeth Peters; Karen E Welty-Wolf; Bryan D Kraft; R Scott Harris; Rie Maurer; Kiichi Nakahira; Clara Oromendia; John D Davies; Angelica Higuera; Kristen T Schiffer; Joshua A Englert; Paul B Dieffenbach; David A Berlin; Susan Lagambina; Mark Bouthot; Andrew I Sullivan; Paul F Nuccio; Mamary T Kone; Mona J Malik; Maria Angelica Pabon Porras; Eli Finkelsztein; Tilo Winkler; Shelley Hurwitz; Charles N Serhan; Claude A Piantadosi; Rebecca M Baron; B Taylor Thompson; Augustine Mk Choi
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  "CO in a pill": Towards oral delivery of carbon monoxide for therapeutic applications.

Authors:  Xiaoxiao Yang; Wen Lu; Minjia Wang; Chalet Tan; Binghe Wang
Journal:  J Control Release       Date:  2021-09-02       Impact factor: 11.467

3.  Effects of inhaled CO administration on acute lung injury in baboons with pneumococcal pneumonia.

Authors:  Laura E Fredenburgh; Bryan D Kraft; Dean R Hess; R Scott Harris; Monroe A Wolf; Hagir B Suliman; Victor L Roggli; John D Davies; Tilo Winkler; Alex Stenzler; Rebecca M Baron; B Taylor Thompson; Augustine M Choi; Karen E Welty-Wolf; Claude A Piantadosi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-28       Impact factor: 5.464

4.  A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.

Authors:  Ivan O Rosas; Hilary J Goldberg; Harold R Collard; Souheil El-Chemaly; Kevin Flaherty; Gary M Hunninghake; Joseph A Lasky; David J Lederer; Roberto Machado; Fernando J Martinez; Rie Maurer; Danielle Teller; Imre Noth; Elizabeth Peters; Ganesh Raghu; Joe G N Garcia; Augustine M K Choi
Journal:  Chest       Date:  2017-10-31       Impact factor: 9.410

Review 5.  A review of the experimental evidence on the toxicokinetics of carbon monoxide: the potential role of pathophysiology among susceptible groups.

Authors:  Prabjit Barn; Luisa Giles; Marie-Eve Héroux; Tom Kosatsky
Journal:  Environ Health       Date:  2018-02-05       Impact factor: 5.984

Review 6.  Carbon monoxide in intensive care medicine-time to start the therapeutic application?!

Authors:  Ulrich Goebel; Jakob Wollborn
Journal:  Intensive Care Med Exp       Date:  2020-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.